Tachibana provided third quarter 2025 guidance of total company revenue in the range of $12 million to $14 million and pharma test/services revenue in the range of $11 million to $13 million.
Hosted on MSN
Castle Biosciences raises 2025 revenue guidance to $310M–$320M following strong Q2 execution and test volume growth
The company raised 2025 total revenue guidance to $310 million–$320 million. Stokes explained that “our normalized revenue growth range in 2025 would be approximately 21% to 26%” when excluding ...
In today’s competitive semiconductor market, revenue growth is often associated with design innovation, process advancements, or packaging breakthroughs. However, a powerful and frequently overlooked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results